These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 34948114)

  • 1. Targeting Non-Replicating
    Egorova A; Salina EG; Makarov V
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.
    Getahun H; Matteelli A; Abubakar I; Aziz MA; Baddeley A; Barreira D; Den Boon S; Borroto Gutierrez SM; Bruchfeld J; Burhan E; Cavalcante S; Cedillos R; Chaisson R; Chee CB; Chesire L; Corbett E; Dara M; Denholm J; de Vries G; Falzon D; Ford N; Gale-Rowe M; Gilpin C; Girardi E; Go UY; Govindasamy D; D Grant A; Grzemska M; Harris R; Horsburgh CR; Ismayilov A; Jaramillo E; Kik S; Kranzer K; Lienhardt C; LoBue P; Lönnroth K; Marks G; Menzies D; Migliori GB; Mosca D; Mukadi YD; Mwinga A; Nelson L; Nishikiori N; Oordt-Speets A; Rangaka MX; Reis A; Rotz L; Sandgren A; Sañé Schepisi M; Schünemann HJ; Sharma SK; Sotgiu G; Stagg HR; Sterling TR; Tayeb T; Uplekar M; van der Werf MJ; Vandevelde W; van Kessel F; van't Hoog A; Varma JK; Vezhnina N; Voniatis C; Vonk Noordegraaf-Schouten M; Weil D; Weyer K; Wilkinson RJ; Yoshiyama T; Zellweger JP; Raviglione M
    Eur Respir J; 2015 Dec; 46(6):1563-76. PubMed ID: 26405286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection.
    Borisov AS; Bamrah Morris S; Njie GJ; Winston CA; Burton D; Goldberg S; Yelk Woodruff R; Allen L; LoBue P; Vernon A
    MMWR Morb Mortal Wkly Rep; 2018 Jun; 67(25):723-726. PubMed ID: 29953429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study.
    Surey J; Stagg HR; Yates TA; Lipman M; White PJ; Charlett A; Muñoz L; Gosce L; Rangaka MX; Francis M; Hack V; Kunst H; Abubakar I
    BMC Infect Dis; 2021 Jan; 21(1):90. PubMed ID: 33478428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection.
    Zhang T; Li SY; Williams KN; Andries K; Nuermberger EL
    Am J Respir Crit Care Med; 2011 Sep; 184(6):732-7. PubMed ID: 21659613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine.
    McClintock AH; Eastment M; McKinney CM; Pitney CL; Narita M; Park DR; Dhanireddy S; Molnar A
    BMC Infect Dis; 2017 Feb; 17(1):146. PubMed ID: 28196479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
    Sharma SK; Sharma A; Kadhiravan T; Tharyan P
    Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD007545. PubMed ID: 23828580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isoniazid and Rifapentine Treatment Eradicates Persistent
    Foreman TW; Bucşan AN; Mehra S; Peloquin C; Doyle LA; Russell-Lodrigue K; Gandhi NR; Altman J; Day CL; Ernst JD; Blumberg HM; Rengarajan J; Kaushal D
    Am J Respir Crit Care Med; 2020 Feb; 201(4):469-477. PubMed ID: 31647877
    [No Abstract]   [Full Text] [Related]  

  • 9. Three months of weekly rifapentine plus isoniazid for latent tuberculosis treatment in solid organ transplant candidates.
    Knoll BM; Nog R; Wu Y; Dhand A
    Infection; 2017 Jun; 45(3):335-339. PubMed ID: 28276008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment for latent tuberculosis infection in low- and middle-income countries: progress and challenges with implementation and scale-up.
    Harries AD; Kumar AMV; Satyanarayana S; Takarinda KC; Timire C; Dlodlo RA
    Expert Rev Respir Med; 2020 Feb; 14(2):195-208. PubMed ID: 31760848
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of latent tuberculosis infection.
    Parekh MJ; Schluger NW
    Ther Adv Respir Dis; 2013 Dec; 7(6):351-6. PubMed ID: 24056289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study.
    Doan TN; Fox GJ; Meehan MT; Scott N; Ragonnet R; Viney K; Trauer JM; McBryde ES
    J Antimicrob Chemother; 2019 Jan; 74(1):218-227. PubMed ID: 30295760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress on diagnosis and treatment of latent tuberculosis infection.
    Ying C; He C; Xu K; Li Y; Zhang Y; Wu W
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Dec; 51(6):691-696. PubMed ID: 36915977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of latent tuberculosis infection: a network meta-analysis.
    Stagg HR; Zenner D; Harris RJ; Muñoz L; Lipman MC; Abubakar I
    Ann Intern Med; 2014 Sep; 161(6):419-28. PubMed ID: 25111745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Latent Tuberculosis Infection Among Healthcare Workers: 10-Year Experience at a Single Center.
    Arguello Perez E; Seo SK; Schneider WJ; Eisenstein C; Brown AE
    Clin Infect Dis; 2017 Nov; 65(12):2105-2111. PubMed ID: 29020308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses.
    Pease C; Hutton B; Yazdi F; Wolfe D; Hamel C; Quach P; Skidmore B; Moher D; Alvarez GG
    BMC Infect Dis; 2017 Apr; 17(1):265. PubMed ID: 28399802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Latent tuberculosis infection: Opportunities and challenges.
    Chee CBE; Reves R; Zhang Y; Belknap R
    Respirology; 2018 Oct; 23(10):893-900. PubMed ID: 29901251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection.
    Holland DP; Sanders GD; Hamilton CD; Stout JE
    PLoS One; 2011; 6(7):e22276. PubMed ID: 21789248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher Completion Rates With Self-administered Once-weekly Isoniazid-rifapentine Versus Daily Rifampin in Adults With Latent Tuberculosis.
    Haas MK; Aiona K; Erlandson KM; Belknap RW
    Clin Infect Dis; 2021 Nov; 73(9):e3459-e3467. PubMed ID: 32915203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Completion Rate for 12 Weekly Doses of Isoniazid and Rifapentine as Treatment for Latent Mycobacterium tuberculosis Infection in the Federal Bureau of Prisons.
    Schmit KM; Lobato MN; Lang SG; Wheeler S; Kendig NE; Bur S
    J Public Health Manag Pract; 2019; 25(2):E1-E6. PubMed ID: 30024493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.